Pre-surgical Clinical Validation Archives - Agendia

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
Gallery
Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

BluePrint, Evidence, NBRST, Neoadjuvant

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

PUBLICATION: Ann Surg Oncol. 2017 Sep;24(9):2539-2546. doi: 10.1245/s10434-017-5863-x. AUTHORS: Peter Read More

kevin2024-03-25T09:14:21-07:00April 26th, 2017|BluePrint, Evidence, NBRST, Neoadjuvant|

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping
Gallery
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

BluePrint, Evidence, NBRST, Neoadjuvant

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

PUBLICATION: Annals of Surgical Oncology; March 2017, Volume 24, Issue Read More

kevin2024-03-25T09:16:48-07:00October 21st, 2016|BluePrint, Evidence, NBRST, Neoadjuvant|

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures
Gallery
Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

BluePrint, Evidence, NBRST, Neoadjuvant

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

PUBLICATION: Ann Surg Oncol (2016) 23: 3317. https://doi.org/10.1245/s10434-016-5329-6. AUTHORS: Peter Read More

kevin2024-03-25T09:19:31-07:00July 6th, 2016|BluePrint, Evidence, NBRST, Neoadjuvant|

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy
Gallery
Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy

BluePrint, Evidence, NBRST, Neoadjuvant

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy

PUBLICATION: Ann Surg Oncol (2016) 23: 1522. https://doi.org/10.1245/s10434-015-5030-1. AUTHORS: Paul Read More

kevin2024-03-25T09:21:21-07:00May 1st, 2016|BluePrint, Evidence, NBRST, Neoadjuvant|

Molecular Subtyping Predicts Pathologic Tumor Response in Early-Stage Breast Cancer Treated with Neoadjuvant Docetaxel Plus Capecitabine with or without Trastuzumab Chemotherapy
Gallery
Molecular Subtyping Predicts Pathologic Tumor Response in Early-Stage Breast Cancer Treated with Neoadjuvant Docetaxel Plus Capecitabine with or without Trastuzumab Chemotherapy

BluePrint, Evidence, Neoadjuvant

Molecular Subtyping Predicts Pathologic Tumor Response in Early-Stage Breast Cancer Treated with Neoadjuvant Docetaxel Plus Capecitabine with or without Trastuzumab Chemotherapy

PUBLICATION: Med Oncol. (2014) 31: 163. https://doi.org/10.1007/s12032-014-0163-9. AUTHORS: Soley Bayraktar, Read More

kevin2024-03-25T10:18:35-07:00September 4th, 2014|BluePrint, Evidence, Neoadjuvant|

Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy
Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy

BluePrint, Evidence, Neoadjuvant

Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy

PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):759-67. doi: 10.1007/s10549-013-2572-4. AUTHORS: Read More

kevin2024-03-25T10:46:58-07:00June 12th, 2013|BluePrint, Evidence, Neoadjuvant|

Agendia precision oncology

Quick Links

Our Tests
Resources
Landmark Trials
Order A Test
For Patients

Legal

Privacy Policy
Legal & Compliance
Terms & Conditions
Licenses & Accreditations
Code of Conduct

Contact

For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com

For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com

©2024 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.